Science · 9 min read · 21 March 2026
CRISPR Gene Therapy Shows Promise for Sickle Cell in Landmark Trial
T
Thomas Keller
Science Correspondent · 21 March 2026 · 9 min read
Listen to this article — available with membership ($3/month)
Science
A Phase III trial reports a 94% reduction in pain crises among patients treated with the gene-editing therapy, raising hopes for a functional cure.
This is a preview. The full article will be available when content is loaded from the CMS.
Share